Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 34

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Paroxysmal nocturnal haemoglobinuria16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Cardiogenic shock

Not yet recruiting

High-dose insulin lispro, potassium chloride and glucose treatment for patients with non‑toxic acute cardiogenic shock

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Oslo University Hospital HF

Pulmonary hypertension

Not yet recruiting

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

Cardiovascular disorder

Not yet recruiting

Rosuvastatin zinc 20 mg for patients with cardiovascular disease and statin intolerance: a trial comparing continuation after a 36‑week N‑of‑1 self‑assessment versus standard care

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rosuvastatin Zinc
  • Sponsor:Copenhagen University Hospital

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Arteriovenous malformation

Not yet recruiting

Long‑Term Effects of Sirolimus on Volume and Color of Port‑Wine Stain in Patients with Vascular Malformation Undergoing Surgery and Laser Therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Sirolimus
  • Sponsor:Oslo University Hospital HF

Granulomatosis with polyangiitis+1

Not yet recruiting

Rituximab versus clinic‑biological monitoring for ANCA reactivation in patients with GPA or MPA (with prednisolone)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary embolism

Not yet recruiting

Enoxaparin or drug combination versus no anticoagulant treatment for incidental subsegmental pulmonary embolism in cancer patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Region Hovedstaden

Subarachnoid haemorrhage

Not yet recruiting

Ticagrelor versus placebo to prevent cerebral ischemia in patients with low‑grade aneurysmal subarachnoid hemorrhage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ticagrelor
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Coronary artery disease

Not yet recruiting

Prognostic H2[15O] PET Imaging Study in Patients with Coronary Artery Disease Using O15‑Water, Adenosine and Regadenoson

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Vaestra Goetalandsregionen

Pulmonary arterial hypertension+1

Not yet recruiting

Vasopressin Versus Norepinephrine for Patients with Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Fondation Hopital Saint Joseph

Granulomatosis with polyangiitis

Not yet recruiting

Study of Empagliflozin, Losartan Potassium and Hydrochlorothiazide to Prevent Kidney Stones in Patients with Paraffin Oil Induced Granulomatous Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Empagliflozin
  • Sponsor:Region Hovedstaden

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.